Speaker Biographies (in alphabetical order)
Mitchell Cohen, MD
Dr. Mitchell Jay Cohen has a strong history in the study of coagulation and inflammatory perturbations after injury and shock his research has been instrumental in characterizing these perturbations after injury. He has extensive experience in the functional study of coagulation and assay coagulation and inflammatory biomarkers after severe injury. His lab now is working to apply cellular therapeutics to these injuries both at the lab and translational level. In addition to his role as a clinical and basic science investigator, he is a clinically busy trauma and acute care surgeon and intensivist. He is currently the Associate Director of Trauma at the San Francisco General Hospital and an Associate Professor of Surgery In Residence at the University of California San Francisco. His unique dual role as a busy trauma surgeon and intensivist and research experience provide a unique translational understanding of the physiologic, biologic and clinical sequalie of severe injury and shock. Dr. Cohen has extensive organizational and leadership roles in multiple organizations and has most recently served as the program chair for the International Conference on Complexity In Acute Illness.
David Courtman, PhD
Dr. Courtman is trained in cellular and molecular pathology and biophysics with extensive expertise in the development of novel therapies for cardiovascular disease. He has a long standing interest in the development of novel cardiovascular biomaterials and the regulation of biological responses within the unique spatially oriented matricellular environment of blood vessels. He has also participated in the development of a number of cellular based gene therapies for the treatment of cardio-pulmonary disorders taking them from initial concept, through appropriate animal disease models, and into first-in-human clinical trials. Dr Courtman is currently directing the manufacturing of these cell products for trials treating patients suffering from pulmonary arterial hypertension, myocardial infarction, and sepsis. He is a Scientist and Direct of Biotherapeutics at the Ottawa Hospital Research Institute, Assistant Professor at the University of Ottawa, and Chief Scientific Officer of Northern Therapeutics.
Charles S. Cox, Jr., MD
Dr. Charles S. Cox, Jr., is the Children’s Fund, Inc. Distinguished Professor of Pediatric Surgery and directs the Pediatric Surgical Translational Laboratories and Pediatric Program in Regenerative Medicine at the University of Texas Medical School at Houston. He directs the Pediatric Trauma Program at the University of Texas-Houston/Children’s Memorial Hermann Hospital in the Texas Medical Center. Dr. Cox received his MD at the University of Texas Medical Branch at Galveston. He completed his Surgery residency at the University of Texas Medical School at Houston followed by further post-graduate fellowships in Pediatric Surgery at the University of Michigan, an NIH T32 sponsored clinical and research fellowship in cardiopulmonary support/circulatory support devices/bio-hybrid organs at the Shriners Burns Institute, and a Surgical Critical Care fellowship at the University of Texas Medical School at Houston. Under Dr. Cox’s direction, the Pediatric Translational Laboratories and Pediatric Program in Regenerative Medicine focuses on progenitor cell based therapy for traumatic brain injury, and related neurological injuries (hypoxic-ischemic encephalopathy, stroke, spinal cord injury), recently completing the first acute, autologous cell therapy treatment Phase I study for traumatic brain injury in children. The program also develops novel bio-hybrid organs using cell-based and tissue engineering approaches to trauma and injury related problems. These efforts have recently resulted in two IND based cell therapeutic studies, and three patents in the past two years. Dr. Cox is certified by the American Board of Surgery in Surgery, with added qualifications in Pediatric Surgery and Surgical Critical Care. He has served on scientific study sections/review groups for the National Institutes of Health, American Heart Association, Veterans Affairs MERIT Awards, Department of Defense, Congressionally Directed Medical Research Programs, as well as National Research Programs in Canada, Singapore, and the Czech Republic. He is the author of over 100 scientific publications, 20 book chapters, and is the editor of a text in press entitled, Progenitor Cell Therapy for Neurological Injury.
Marie Csete, MD, PhD
Marie Csete, MD, PhD, has joined AABB’s senior management team to direct the association’s cellular therapy and regenerative medicine activities. Board certified in anesthesiology and critical care, she is adjunct faculty on the liver transplant team in the Department of Anesthesiology at the University of California, San Diego, and previously served as chief scientific officer at the California Institute for Regenerative Medicine. Csete has conducted extensive stem cell and clinical transplantation research and was the founding director of the Emory University/Georgia Institute of Technology Human Embryonic Stem Cell Core facility. She also was the John E. Steinhaus Professor of Anesthesiology at Emory University, where she studied stem cell aging, directed the liver transplant anesthesia team and co-directed the MD/PhD program. Prior to Emory, she was a professor at the medical schools of the University of California, Los Angeles; University of California, San Francisco; and the University of Michigan. Csete has taught courses in anesthesiology, clinical research, cell and developmental biology, neuroscience, ethics, and biomedical engineering, and has substantial industry and academic consulting experience in regenerative medicine. Csete has been an active member of many societies, including the American Society of Anesthesiologists, Society for Neuroscience and International Society for Stem Cell Research, and has served on a number of committees, such as the American Society of Anesthesiologists Committee on Transplantation and the United Network of Organ Sharing Ethics Committee. She has organized or co-organized numerous workshops and conferences. She co-authored the “Manual of Intensive Care Unit Medicine,” and has published nearly 20 book chapters and a hundred academic research papers. She is on the editorial boards of “Stem Cells Translational Medicine,” “Anesthesia and Analgesia,” and the “Encyclopedia of Human Biology,” and is the holder of three United States patents. Csete serves on several national grant review committees. Csete received her medical degree from Columbia University after completing an undergraduate degree in music at Princeton University. Her residency training was at Harvard University/Massachusetts General Hospital and the Tufts University School of Medicine. She received a doctorate in developmental biology from the California Institute of Technology, where her thesis was awarded Caltech’s highest honor for a PhD, the Clauser Prize.
Dana Devine, PhD
Dana Devine is currently the Vice-President, Medical, Scientific and Research Affairs at Canadian Blood Services. She is also Professor of Pathology and Laboratory Medicine at the University of British Columbia, and a founding member of the University’s Centre for Blood Research. She is the Editor-in-Chief of the blood transfusion journal Vox Sanguinis. Dr. Devine completed her research training at Duke University in North Carolina where she obtained the Ph.D. degree. She has a longstanding research career in blood products, transfusion medicine, platelet biology, complement biochemistry, and coagulation.
Cynthia Gregory, PhD
Dr. Cindy Gregory received her Ph.D. in Microbiology and Immunology from Oregon Health & Science University after which she did a research fellowship at Oregon Health & Science University in Cardiovascular Medicine focusing on the mechanism of cardiac chronic graft rejection. Since that time she has maintained a laboratory at the Portland Veterans Affairs Medical Center, with a research program centered on the regulation of cellular immune responses. Her research was one of the first programs to demonstrate that endothelial cells can be active targets of an immune response, particularly as targets in allograft rejection. Other focus areas have included studies on the role of infectious agents in exacerbating graft rejection (i.e., Cytomegalovirus) and in their ability to serve as vaccine vectors (i.e., Listeria monocytogenes). Dr. Gregory also has studied the regulation of cellular immune responses to autoantigens utilizing rodent models of experimental allergic encephalomyelitis. A current research area of focus is the ability of mesenchymal stromal cells to modulate inflammation and immunity. Since joining Oregon Biomedical Engineering Institute and the Oregon Health & Science University Center for Regenerative Medicine, a primary research focus has been the development of a large animal model of acute lung injury to be used in pre-clinical studies assessing the therapeutic efficacy of mesenchymal stromal cells to modulate acute lung injury inflammation.
Benjamin S. Harrison, PhD
Dr. Benjamin S. Harrison is an associate professor at the Wake Forest Institute for Regenerative Medicine. After receiving a PhD in chemistry from the University of Florida, he has focused his research efforts onto developing new biomaterials and nanomaterials for improving engineered cell and tissue viability. He also serves as the Chief Operating Officer for the Armed Forces Institute for Regenerative Medicine (AFIRM) Wake Forest Pittsburgh Consortium. Through AFIRM network he manages over 200+ scientists and clinicians in their efforts to develop regenerative medicine therapies for the wounded warrior in the areas of burn treatment, craniofacial injuries, compartment syndrome, limb and digit regeneration, and healing without scar.
Aby Mathew, PhD
Dr. Mathew was part of the founding team of BioLife Solutions, and is a co-developer of BioLife’s biopreservation media solutions. He holds a Ph.D. in Biological Sciences within the Biochemistry, Cell and Molecular Biology Program from Binghamton University and a B.S. in Microbiology from Cornell University. Dr. Mathew has been researching low temperature biopreservation since 1994, and his studies contributed to the development of BioLife’s current commercial HypoThermosol and CryoStor product platforms and intellectual property foundation. Dr. Mathew was part of the scientific team that linked cell death via apoptosis (programmed cell death) to exposure to hypothermic and/or freezing temperatures. These discoveries were integral to the development of BioLife’s improved intracellular-like biopreservation solutions, and also contributed to improvements in cryosurgical ablation of cancer. Dr. Mathew was BioLife’s first Director of Manufacturing, established BioLife’s initial Quality system, and is currently Senior Vice President and Chief Technology Officer for BioLife Solutions. Dr. Mathew is currently active in, or previously a member of, the International Society for Cell Therapy (ISCT), AABB (formerly the American Association of Blood Banks), BEST (the Biomedical Excellence for Safer Transfusion collaborative), Tissue Engineering & Regenerative Medicine International Society (TERMIS), Society for Cryobiology , International Society for Biological and Environmental Repositories (ISBER), American Society for Cell Biology, and the Society for In Vitro Biology. Dr. Mathew is a member of the ISCT Commercialization Committee, AABB Product Manufacturing and Testing subsection, AABB Novel Therapies and Product Development subsection, and the Parent’s Guide to Cord Blood Foundation Advisory Panel.
Michael Matthay, MD
Michael A. Matthay, MD is a Professor of Medicine and Anesthesia at the University of California at San Francisco and a Senior Associate at the Cardiovascular Research Institute. He is Director of the Critical Care Medicine Training in the Department of Medicine and Associate Director of the Intensive Care Unit. He received his AB from Harvard University in 1969 and his MD from the University of Pennsylvania School of Medicine in 1973. Dr. Matthay received clinical training in Internal Medicine at the University of Colorado from 1973-76 and in Pulmonary and Critical Care Medicine from the University of California at San Francisco from 1977-78. He also received research training from the Cardiovascular Physiology Laboratory, University of Colorado in 1976 and the Cardiovascular Research Institute from 1978-79. He is a former Chairman of the Respiration Section of the American Physiological Society and he served as a member (1995-2000) and chair (1998-2000) of the NIH Lung Biology and Pathology study section. He received an American Thoracic Society award for Scientific Achievement in 2002. He is a member of the American Association of Physicians. Dr. Matthay’s basic research is focused on active ion, solute, water, and protein transport mechanisms across the alveolar epithelium that account for the resolution of pulmonary edema. He has also studied the function of the alveolar epithelium under conditions of acute lung injury. The studies are carried out with both in vivo and in vitro models. Dr. Matthay’s clinical research is focused on the mechanisms that account for the pathogenesis and resolution of clinical acute lung injury and pulmonary edema. His most recent work has focused on the potential therapeutic value of mesenchymal stem cells for the treatment of acute lung injury.
Robert Mays, PhD
Since co-founding Athersys in 1995, Dr. Mays has directed the drug discovery applications of Athersys' cell biological platform technologies. Currently, Dr. Mays is the Head of Neurosciences and the Senior Director of Regenerative Medicine and is focused on the development of Athersys' novel human stem cell product MultiStem®. Specifically, he is focused on the applications of MultiStem in Regenerative Medicine, with a focus on injuries and diseases affecting the central nervous system. He received his BS from Carnegie Mellon in 1987, and his Ph.D. from Stanford University in Molecular and Cellular Physiology. He subsequently studied as a visiting scholar at the University of Utrecht, the Weizmann Institute and at the University of California, San Francisco. He is currently an adjunct professor at Case Western Reserve University and on faculty at the Center for Stem Cell and Regenerative Medicine and the National Center for Regenerative Medicine.
David McKenna, MD
David McKenna, MD, is an associate professor and director of the Division of Transfusion Medicine in the Department of Laboratory Medicine and Pathology at the University of Minnesota Medical School. In addition, he serves as scientific and medical director of Molecular and Cellular Therapeutics, the cGMP facility of the University of Minnesota, and laboratory and medical director of the University of Minnesota Medical Center's Clinical Cell Therapy Laboratory. His lab supports the Blood and Marrow Transplant Program (250 transplants/year, including 100 double cord blood transplants/year) as well as nearly 20 INDs for novel cell therapy clinical trials involving mesenchymal stromal cells, dendritic cells, natural killer cells, T regulatory cells, cord blood expansion, and marrow mononuclear cells for cardiac applications.
C. Randal Mills, PhD
Bio coming soon
Kim Nguyen, PhD
Kim Nguyen, PhD currently serves as the Scientific Lead for the Quantum Cell Expansion System with Terumo BCT in Lakewood, CO. Kim received her AB in Chemistry from Princeton University in 1999, her PhD in Chemistry from Columbia University in 2005, and subsequently completed a postdoctoral fellowship with Josh Hare and Ian McNiece at the University of Miami focused on preclinical process translation and clinical cGMP scale-up of MSC, dendritic cell, and HSC cultures. She also participated in the IND submissions and GMP manufacturing of patient –infused products for four clinical trials based upon the direct injection of MSC into the heart for myocardial infarction and dilated cardiomyopathy indications (PROMETHEUS, TAC-HFT, POSEIDON, and POSEIDON-DCM trials). Kim joined Terumo BCT from the University of Miami in July 2010.
Shibani Pati, MD, PhD
Shibani Pati received her bachelor’s degree in molecular biology from Princeton University and her MD. PhD. from the University of Maryland in Baltimore. Her background is in cancer research and vascular biology. Her main areas of investigation involve the use of adult bone marrow derived stem cells and plasma based resuscitative modalities to mitigate endothelial dysfunction in traumatic injury, specifically traumatic brain injury (TBI) and hemorrhagic shock. She is currently an Assistant Investigator at Blood Systems Research Institute (BSRI), San Francisco and the University of California San Francisco - Department of Laboratory Medicine. She leads the Stem Cell Therapeutics and Vascular Biology group at BSRI and the mission of this group is to investigate novel therapeutics that can mitigate vascular injury and outcome in critically ill patients.
Jon Rowley, PhD
Jon A. Rowley, PhD, is the Innovation Director of Cell Processing Technologies at Lonza Biosciences, responsible for driving technology development and innovation related to commercial scale bioprocessing of therapeutic cell-based products. Jon’s personal goal is to the have the biggest impact possible on the commercial translation of cell-based therapies. He is heavily involved with the International Society for Cell Therapy as a member of the Commercialization Committee, and is chairing a subcommittee related to Process and Product Development. Jon holds a PhD from the University of Michigan in Biomedical Engineering and has authored over 25 peer reviewed manuscripts and 15 issued or pending patents related to biomaterials development, tissue engineering, and cellular therapy. Jon spent several years at BD as a scientist and R&D manager in a Cell & Tissue Technologies group focused on applying high throughput screening technologies to cell therapy media development and tissue engineering. Jon then contributed to the clinical development of Aastrom Biosciences’ Tissue Repair Cell product, where he was Sr Manager of Process Development responsible for manufacturing process improvements and cell delivery to the patient. Jon joined Lonza’s Cell Therapy business in March of 2008, and currently resides in Walkersville, MD with his wonderful wife and their 3 young children.
Philip Spinella, MD
Dr Philip C. Spinella is a pediatric intensivist and Director of the Critical Care Translational Research Program and the Blood Research Program at Washington University in St. Louis School of Medicine and the St. Louis Children’s Hospital. He served as an active duty US Army physician for 12 years, which included a 1-year deployment to Iraq. He continues to serve as a Consultant to the US Army Blood Research Program and is the Chair of the Steering Committee for the Norwegian Navy Blood Far Forward Research Program. His publications are in the area of blood component and whole blood resuscitation for traumatic hemorrhagic shock, clinical and translational research regarding the effects of RBC storage duration on outcomes, immunology and coagulation, and coagulation monitoring by thromboelastography. He is also an Affiliate Investigator at the Blood Systems Research Institute in San Francisco, CA. He is the Chair of two international research networks; Pediatric Critical Care Blood Research Network (Blood Net) and the Trauma Hemorrhage and Oxygenation Research (THOR) Network. Dr Spinella’s current funded research projects examine the immunologic, coagulation, and vasoregulatory effects of RBC transfusion according to storage age in two large RCTs (ABLE and RECESS).
David Stroncek, MD
David Stroncek, MD is the current Chief of the Cell Processing Section in the Department of Transfusion Medicine at the National Institutes of Health. Dr. Stroncek directs three related laboratories: a clinical cell processing laboratory that manufactures all cell and gene therapies for NIH Clinical Center patients, a product development laboratory and a research laboratory. The product development laboratory has developed novel NK cell, dendritic cell and T cell therapies and gene therapies and is actively developing several new cellular and gene therapies. Dr. Stroncek's research laboratory is currently focused on developing new cellular and gene therapies, improving existing cellular and gene therapies, understanding the critical functions of successful cellular and gene therapies and developing better assays and discovering new biomarkers for gene therapies.